Leading specialty pharmaceutical company in the renal disease area with its leading drug Nefecon in late stage clinical development indicated for patients with inflammatory kidney disease. We invested in Calliditas at an early stage based on the world-class science behind the leading drug candidate today in late stage development, combined with the great unmet need shown in inflammatory kidney disease. Calliditas is today listed on NASDAQ Stockholm (CALTX).
Renal disease has had several breaktroughs in terms of new advanced treatments in the past decade. IgA nephrophathy – also known as Berger’s disease – is the most common form of chronic inflammatory condition of the kidney. Today there are no approved treatments for this condition. Calliditas has with its lead drug candidate in Nefecon been granted orphan drug designation by regulatory authorities worldwide.